Cost–effectiveness of strontium ranelate for the prevention and treatment of osteoporosis

References

• Hiligsmann M, Bruyere O, Ethgen O, Gathon HJ, Reginster JY. Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. Bone43, 991–994 (2008).
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos. Int.11, 669–674 (2000).
   PubMed Web of Science ®Google Scholar
• Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos. Int.7, 407–413 (1997).
   PubMed Web of Science ®Google Scholar
• Kanis JA, Burlet N, Cooper C et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int.19, 399–428 (2008).
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med.350, 459–468 (2004).
   PubMed Web of Science ®Google Scholar
• Reginster JY, Felsenberg D, Boonen S et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum.58, 1687–1695 (2008).
   PubMed Web of Science ®Google Scholar
• Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab.90, 2816–2822 (2005).
   PubMed Web of Science ®Google Scholar
• Seeman E, Devogelaer JP, Lorenc R et al. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J. Bone Miner. Res.23, 433–438 (2008).
   PubMedGoogle Scholar
• Reginster JY, Bruyere O, Sawicki A et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone45, 1059–1064 (2009).
   PubMed Web of Science ®Google Scholar
• Marie PJ, Hott M, Modrowski D et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J. Bone Miner. Res.8, 607–615 (1993).
   PubMed Web of Science ®Google Scholar
• Neuprez A, Hiligsmann M, Scholtissen S, Bruyere O, Reginster JY. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis. Adv. Ther.25, 1235–1256 (2008).
   PubMed Web of Science ®Google Scholar
• Jonville-Bera AP, Crickx B, Aaron L, Hartingh I, Autret-Leca E. Strontium ranelate-induced DRESS syndrome: first two case reports. Allergy64, 658–659 (2009).
   PubMed Web of Science ®Google Scholar
• Pernicova I, Middleton ET, Aye M. Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert. Osteoporos. Int.19, 1811–1812 (2008).
   PubMedGoogle Scholar
• Musette P, Brandi ML, Cacoub P, Kaufman JM, Rizzoli R, Reginster JY. Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos. Int.21, 723–732 (2010).
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Ethgen O, Bruyere O, Richy F, Gathon HJ, Reginster JY. Development and validation of a Markov Microsimulation Model for the economic evaluation of treatments in osteoporosis. Value Health12, 687–696 (2009).
   PubMed Web of Science ®Google Scholar
• Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B. Cost-effectiveness of the treatment and prevention of osteoporosis – a review of the literature and a reference model. Osteoporos. Int.18, 9–23 (2007).
   PubMed Web of Science ®Google Scholar
• Borgstrom F, Jonsson B, Strom O, Kanis JA. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos. Int.17, 1781–1793 (2006).
   PubMed Web of Science ®Google Scholar
• Borgstrom F, Strom O, Coelho J et al. The cost–effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos. Int.21, 339–349 (2010).
   PubMedGoogle Scholar
• Hiligsmann M, Bruyere O, Reginster JY. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Bone46, 440–446 (2010).
   PubMedGoogle Scholar
• Hiligsmann M, Bruyere O, Reginster JY. Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos. Int.21, 157–165 (2010).
   PubMedGoogle Scholar
• Stevenson M, Davis S, Lloyd-Jones M, Beverley C. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol. Assess.11, 1–134 (2007).
   PubMed Web of Science ®Google Scholar
• Seeman E, Boonen S, Borgstrom F et al. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone46, 1038–1042 (2010).
   PubMed Web of Science ®Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med. Decis. Making13, 322–338 (1993).
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M, Claxton K. Modelling Methods for Health Economic Evaluation. Oxford University Press, NY, USA (2006).
   Google Scholar
• Hunink M, Glasziou P, Siegel J et al.Decision Making in Health and Medicine: Integrating Evidence and Values. University Press, Cambridge, UK (2001).
   Google Scholar
• Vanness DJ, Tosteson AN, Gabriel SE, Melton LJ 3rd. The need for microsimulation to evaluate osteoporosis interventions. Osteoporos. Int.16, 353–358 (2005).
   Google Scholar
• Meunier PJ, Roux C, Ortolani S et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos. Int.20, 1663–1673 (2009).
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Slosman DO, Delmas PD et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis – a 2-year randomized placebo controlled trial. J. Clin. Endocrinol. Metab.87, 2060–2066 (2002).
   PubMed Web of Science ®Google Scholar
• Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos. Int.13, 925–931 (2002).
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif. Tissue Int.86, 202–210 (2010).
   Web of Science ®Google Scholar
• Fleurence RL, Iglesias CP, Johnson JM. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics25, 913–933 (2007).
   PubMed Web of Science ®Google Scholar
• Fleurence RL, Iglesias CP, Torgerson DJ. Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporos. Int.17, 29–40 (2006).
   PubMed Web of Science ®Google Scholar
• Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr. Rev.23, 570–578 (2002).
   PubMed Web of Science ®Google Scholar
• Borgstrom F, Kanis JA. Health economics of osteoporosis. Best Pract. Res. Clin. Endocrinol. Metab.22, 885–900 (2008).
   PubMed Web of Science ®Google Scholar
• Adachi JD, Kennedy CC, Papaioannou A, Ioannidis G, Leslie WD, Walker V. Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers? Osteoporos. Int.20, 1785–1793 (2009).
   PubMedGoogle Scholar
• Rabenda V, Mertens R, Fabri V et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos. Int.19, 811–818 (2008).
   PubMed Web of Science ®Google Scholar
• Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos. Int.17, 1645–1652 (2006).
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Rabenda V, Bruyère O, Reginster J. The clinical and economic burden of non-adherence with osteoporosis medications. Health Policy97, 170–176 (2010).
   Google Scholar
• Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Ann. Rheum. Dis.58(Suppl. 1), I82–I85 (1999).
   PubMed Web of Science ®Google Scholar
• Rabenda V, Reginster JY. Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporos. Int. DOI: 10.1007/s00198-009-1155-z (2010) (Epub Ahead of Print).
   PubMedGoogle Scholar
• Breart G, Jakob FJ, Palacios S et al. New interim analysis of a prospective observational cohort study of patients treated with strontium ranelate. Osteoporos. Int.21(Suppl. 1), S166 (2010).
   Google Scholar
• Drummond M, Barbieri M, Cook J et al. Transferability of economic evaluations across juridictions: ISPOR good research practices task force report. Value Health12, 409–418 (2009).
   PubMed Web of Science ®Google Scholar
• Roux C, Fechtenbaum J, Kolta S, Isaia G, Cannata Andia JB, Devogelaer JP. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann. Rheum. Dis.67, 1736–1738 (2008).
   PubMed Web of Science ®Google Scholar
• Fleurence RL, Spackman DE, Hollenbeak C. Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis. Pharmacoeconomics28, 295–306 (2010).
   PubMedGoogle Scholar